Sign In
Buy NVAX
$10.20
-0.0100 (-0.0979%)
At Close: Jun 03, 2026
Is Novavax Stock A Sell After New Covid Shot Fails To Bolster Its Outlook?
12:23pm, Friday, 17'th Nov 2023
Novavax stock is on the downswing again after the company cut its outlook for the year. Is NVAX stock a buy or a sell right now?
Where Will Novavax Be in 3 Years?
05:30am, Saturday, 11'th Nov 2023
Novavax has struggled since its coronavirus vaccine reached the market after the vaccines of rivals. But the company has launched a cost-cutting plan and aims to bring a new game-changing vaccine to m
Novavax, Inc. (NVAX) Q3 2023 Earnings Call Transcript
02:04pm, Thursday, 09'th Nov 2023
Novavax, Inc. (NASDAQ:NVAX ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director, IR John Jacob - President & CEO John Trizzino - Chief Co
Novavax shares rise as third quarter results top expectations
08:50am, Thursday, 09'th Nov 2023
Novavax Inc. shares NVAX, -4.09% moved slightly higher premarket on Thursday after the company reported a narrower-than-expected third quarter loss but trimmed its 2023 sales guidance.
COVID vaccine maker Novavax reports better-than-expected revenue
07:52am, Thursday, 09'th Nov 2023
COVID-19 vaccine maker Novavax on Thursday beat Wall Street estimates for third-quarter revenue, boosted by U.S. government grants to help cover the expense of clinical trials, sending its shares up n
Novavax could become a penny stock: beware of the Wyckoff theory
07:44am, Friday, 03'rd Nov 2023
Novavax (NASDAQ: NVAX) stock price has been a huge disappointment among investors in the past few months. After peaking at $332 during the Covid-19 pandemic, the shares have tumbled to $7.
Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?
10:00am, Thursday, 02'nd Nov 2023
Novavax shares currently trade at an extremely modest price-to-sales ratio. The company has previously raised concerns about its ability to survive as a business.
Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023
09:25am, Thursday, 02'nd Nov 2023
GAITHERSBURG, Md. , Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its thir
7 Dangerous Stocks to Avoid No Matter What
10:43am, Wednesday, 01'st Nov 2023
While the jury's still out whether the economy and the market is headed for a soft or hard landing, as interest rates remain high, that doesn't mean you should forget about which stocks to avoid. Even
Novavax Maintains Covid-19 Shot Rollout Optimism
10:55am, Tuesday, 17'th Oct 2023
Novavax Inc (NASDAQ:NVAX) expressed optimism about the availability of its updated Covid-19 vaccine, now being rolled out in the U.S. The biotech name is also working with the European Medicines Agen
Do These 5 Words From Pfizer Mean Trouble for Novavax?
06:00am, Tuesday, 17'th Oct 2023
Pfizer, Moderna, and Novavax each are vying for a share of the vaccine market this fall. Big pharma company Pfizer recently updated its financial guidance for the year.
Novavax positive on updated COVID vaccine availability in US
04:05pm, Monday, 16'th Oct 2023
Novavax said on Monday it was "encouraged" by the broad availability of its updated COVID-19 vaccine being rolled out in the U.S., days after rival Pfizer slashed its full-year revenue forecast.
Is Novavax Stock a Buy Now?
06:34am, Monday, 16'th Oct 2023
Novavax's coronavirus vaccine is one of the few currently authorized in the U.S. However, the company's competition is fierce in a market whose size is difficult to estimate. Novavax could be successf
EU delays approval of Novavax's revised COVID vaccine - FT
12:24am, Sunday, 15'th Oct 2023
European Union (EU) regulators have delayed the decision to give approval for Novavax's variant-tailored COVID-19 vaccine, the Financial Times said on Sunday.
Novavax (NVAX) Stock Slides Despite Vaccine Availability
01:38pm, Friday, 13'th Oct 2023
Despite seemingly good news, shares of biotechnology firm Novavax (NASDAQ: NVAX ) suffered a significant decline. Earlier Friday morning, management announced the availability of its Covid-19 vaccine
